Home Alzheimer’s Disease After Platinum-Based Therapy, Liposomal Irinotecan Appears Effective, Safe for Second-Line SCLC

After Platinum-Based Therapy, Liposomal Irinotecan Appears Effective, Safe for Second-Line SCLC

Frontline treatment failure of platinum-based therapy may be followed by liposomal irinotecan in SCLC according to data from the first phase of the RESILIENT trial (NCT03088813) presented at the 2020 World Conference on Lung Cancer showing promising antitumor activity and safety with this strategy.

The study authors initiated the 2-part phase 2/3 open-label, single-arm study to assess liposomal irinotecan in patients with SCLC whose disease progressed after receiving platinum-based chemotherapy in the frontline. Treatment options in the second-line setting remain limited but analyzing long-term follow-up data demonstrated that both exploratory doses of liposomal irinotecan were effective and tolerable in patients with SCLC. Patients who were older than 18, had an ECOG performance score of 0 or 1, and had previously progressed on platinum-based treatments were eligible for the study….

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Recent Comments